Despite manufacturing struggles, Novartis still expects Kymriah to become a blockbuster.
The heavily promoted company’s cell therapy fails a key study in ischaemic stroke.
A top three of early-stage CAR-T presentations from this year’s Ash meeting that you might have missed.
Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
Amid a frenzy of BCMA-targeting multiple myeloma therapies Bluebird Bio’s bb21217 falls neatly into the Goldilocks zone.
Ash presentations suggest that the lead asset Celgene acquired through its $9bn takeover of Juno is undergoing a shift of focus.
In the seven months since its founding the company has attracted $793m of financing. Now it must execute.
The phase III failure of one of Bone Therapeutics’ cell therapies puts its other one under greater pressure than ever.
Companies like Nanjing Legend and Cellular Biomedicine Group continue to attract major financial endorsement from Western big pharma, but the threat of scandal is…